Contrast-enhanced MRI lesions during treatment with interferonβ-1b predict increase in T1 black hole volume in patients with relapsing-remitting multiple sclerosis

Abstract

T1 black holes (BH) have been found to represent focal areas of substantial central nervous system tissue damage in multiple sclerosis (MS) patients. We examined the development of T1 BH over a three-year period of treatment with interferon (IFN)β-1b in a group of 20 patients with relapsing-remitting MS. The number of contrast-enhancing lesions (CEL) after one year of treatment predicted a change in the T1 BH volume in the following two years. In patients without CEL, the T1 BH volume remained stable, whereas it increased in patients with CEL. The occurrence of CEL in patients treated with IFNβ may indicate a heightened risk of accumulating T1 BH.

Keywords

black holes contrast-enhancing lesions IFNβ-1b relapsing-remitting MS

Get full access to this article

View all access options for this article.

References

Van Walderveen MA , Kamphorst W , Scheltens P , van Waesberghe JH , Ravid R , Valk J et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis . Neurology 1998; 50: 1282-1288 .

Truyen L , van Waesberghe JH , van Walderveen MA , van Oosten BW , Polman CH , Hommes OR et al. Accumulation of hypointense lesions (‘black holes’) on T1 spin-echo MRI correlates with disease progression in multiple sclerosis . Neurology 1996; 47: 1469-1476 .

Simon JH , Lull J , Jacobs LD , Rudick RA , Cookfair DL , Herndon RM et al. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group . Neurology 2000; 55: 185-192 .

Kurtzke J. Rating neurologic impairment in multiple sclerosis: an expanded status scale (EDSS) . Neurology 1983; 33: 1444-1452 .

Stone LA , Frank JA , Albert PS , Bash CN , Calabresi PA , Maloni H et al. Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure . Neurology 1997; 49: 862-869 .

Giugni E , Paolillo A , Tomassini V , Mainero C , Gasperini C , Russo P et al. An active scan at 12th month of therapy is associated with a worse clinical response to IFNβeta over the subsequent five years of treatment in RRMS . Program and abstracts of the 55th Annual Conference of American Academy of Neurology, 2003: S31.003-S31.003 (abstract).

Rudick RA , Cutter G , Baier M , Dougherty D , Weinstock-Guttman B , Mass M et al. Gadolinium enhancing lesions as a surrogate marker of interferon response . Mult Scler 2002; 8: S21-S21 (abstract).

Brex P , Molyneux PD , Smiddy P , Barkhof F , Filippi M , Yousry T et al. The effect of IFNβeta-1b on the evolution of enhancing lesions in secondary progressive MS . Neurology 2001; 57: 2185-2190 .

Stü rzebecher S , Wandinger KP , Rosenwald A , Sathyarmoorthy M , Tzou A , Mattar P et al. Expression profiling identifies responder and non-responder phenotypes to interferon-b in multiple sclerosis . Brain 2003; 126: 1419-1429 .

10.

Li SYI , Regal J , Soher BJ , Mannon LJ , Grossman RI , Gonen O. Brain metabolite profiles of T1-hypointense lesions in relapsing-remitting multiple sclerosis . AJNR Am J Neuroradiol 2003; 24: 68-74 .